Abstract:Aging-associated structural alterations and functional decline of the brain microvasculature contribute to the development of cognitive impairment and dementias such as Alzheimer’s disease. The mitochondrial loss and dysfunction appear to play a major role in mechanisms leading to aging-associated changes of the microvasculature, including increased blood brain barrier permeability, vascular rarefication, or decreased branching. SS-31, a small, water-soluble tetra-peptide has been shown to be effective in improving the aging phenotype in healthy, aged rodents as well as in models of neurodegenerative disease. However, the beneficial effects of SS-31 have not been examined on the brain microvascular proteome.We tested the hypothesis that targeting mitochondria with SS-31 rescues aging-associated changes in the brain microvascular proteome.Aged male (> 18 months) C57Bl6/J mice were randomly assigned to the SS-31 treatment (10 mg/kg; i.p.; n = 5) or vehicle saline (n = 5) groups. Mice were treated daily for two weeks. Cerebral blood flow (CBF) was measured using laser speckle imaging at four time points (0, 3, 7, 14 days). Then, cortical microvessels (MVs) containing a mixture of end arterioles, capillaries, and venules, < 70mm, were isolated and used for Orbitrap Eclipse Tribrid mass spectrometry.During the two-week period, baseline CBF was similar between SS-31 and vehicle groups. Bioinformatic analysis showed that treatment with SS-31 resulted in significant differences in protein abundance of cortical MVs vs. vehicle. Twelve percent (107) of the identified 6,266 proteins were mitochondria associated (oxidative phosphorylation, metabolism, the antioxidant defense system) and mitochondrial dynamics were significantly differentially expressed, Our findings suggest that mitochondria are potential therapeutic targets in the aging brain microvasculature, and that changes in the proteome may contribute to the beneficial effects of SS-31 in aging. Our results warrant further study with the inclusion of female animals to investigate the role of sex-differences in the effects of SS-31. This research was supported in part by: IDeA National Resource for Quantitative Proteomics Voucher Program (R24GM137786), Tulane Brain Institute Research Fund Award to IR, NIH HL-148836, NIH AG-063345, NIH AG-075988, the Louisiana Board of Regents Endowed Chairs for Eminent Scholars program to Dr. Busija, P30GM145498, U54 GM104940. The University of Arkansas for Medical Sciences Bioinformatics Core Facility is supported by the Winthrop P. Rockefeller Cancer Institute and National Institutes of Health grant P20GM121293. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Treatment of aged mice with the mitochondria targeted antioxidative peptide SS‐31 protects against hypertension‐induced cerebral microhemorrhages

Treatment with the Mitochondrial‐targeted Antioxidant Peptide SS‐31 Improves Cerebromicrovascular Function in Aged Mice

Treatment with the mitochondrial antioxidant peptide SS‐31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice

The beneficial effects of SS-31 on aging mice cerebral microvasculature

Preventing spontaneous cerebral microhemorrhages in aging mice: a novel approach targeting cellular senescence with ABT263/navitoclax

Abstract 9851: Benefit of Antioxidant Peptide SS-31 Treatment in Attenuating Transverse Aortic Constriction-Induced Pulmonary Arterial Hypertension in Mice

SRT1720 Pretreatment Promotes Mitochondrial Biogenesis of Aged Human Mesenchymal Stem Cells and Improves Their Engraftment in Postinfarct Nonhuman Primate Hearts.

Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice

The mitochondria-targeted small molecule SS31 delays progression of behavioral deficits by attenuating β-amyloid plaque formation and mitochondrial/synaptic deterioration in APP/PS1 mice

Ss31, A Small Molecule Antioxidant Peptide, Attenuates Beta-Amyloid Elevation, Mitochondrial/Synaptic Deterioration And Cognitive Deficit In Samp8 Mice

Mitochondria-Targeted Peptide Reverses Mitochondrial Dysfunction and Cognitive Deficits in Sepsis-Associated Encephalopathy

Chronic Administration of Mitochondrion-Targeted Peptide Ss-31 Prevents Atherosclerotic Development in Apoe Knockout Mice Fed Western Diet

Stroke-Induced Neurological Dysfunction in Aged Mice Is Attenuated by Preconditioning with Young Sca-1+ Stem Cells

Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins

Treatment with the BCL-2/BCL-xL inhibitor senolytic drug ABT263/Navitoclax improves functional hyperemia in aged mice

Chronic β3 adrenergic agonist treatment improves brain microvascular endothelial function and cognition in aged mice

Mitochondria-Targeted Antioxidant SS-31 Attenuates Mitochondrial Dysfunction, Reduces Pyroptosis and Improves Locomotor Functional Recovery After Spinal Cord Injury

Adverse Neurological Effects of Short-Term Sleep Deprivation in Aging Mice Are Prevented by SS31 Peptide

SVHRSP Alleviates Age-Related Cognitive Deficiency by Reducing Oxidative Stress and Neuroinflammation

Mitochondrial derived peptide MOTS‐c prevents the development of heart failure under pressure overload conditions in mice

Mitochondria-targeted antioxidant peptide SS-31 mediates neuroprotection in a rat experimental glaucoma model